Industry executives should think back to an earlier precedent: the move in cancer trials pushed by Genentech more than a decade ago to make mid-stage trials mirror approval studies, with control groups and patients who are randomly assigned either to get the drug or not.
FORBES: How A Failed Alzheimer's Drug Illustrates The Drug Industry's Gambling Problem